We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
Read MoreHide Full Article
Cencora, Inc. (COR - Free Report) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 10.3% year to date compared with the industry’s 7.4% growth. The S&P 500 Index has risen 17.7% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $45.02 billion.
Image Source: Zacks Investment Research
COR’s bottom line is anticipated to improve 11.2% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.59%.
What’s Driving COR’s Growth?
Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the segment in the upcoming quarters.
In the third quarter of fiscal 2024, revenues at U.S. Healthcare Solutions totaled $67.2 billion, up 12.2% year over year. The company continues to witness a strong segmental performance due to growth in all markets and strong demand for specialty products, especially GLP-1 drugs. High demand for the recently approved GLP-1 drugs for diabetes and/or weight loss is likely to continue going forward.
Segmental operating income amounted to $698.3 million, up 9.9% year over year. Higher gross profit (including fees earned from the distribution of government-owned COVID-19 treatments and a gross profit on sales from specialty physician practices) contributed to the upside.
Revenues in the U.S. Healthcare Solutions segment are expected to grow 12-13% in fiscal 2024. Operating income is anticipated to increase 10-12% during the same time frame.
Also, Cencora is expected to benefit from generics growth in the long run, raising investors’ optimism. It is well-positioned to help ensure the smooth entry of its products into the market. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, better economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs and a continued good brand pricing environment should aid. Moreover, the company’s focus on specialty drugs bodes well.
In May, Cencora announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC for approximately $400 million in a private transaction. The company also raised its fiscal 2024 guidance for adjusted earnings per share (EPS), which is now estimated to be in the range of $13.55-$13.65 (previously $13.35-$13.55).
The uptick reflects a lower weighted average diluted share count, partially offset by higher net interest expense due to lower investment balances of cash being used for share repurchases. COR estimates revenues to grow 12% year over year. Total adjusted operating income is expected to improve 10-11% during the same time frame.
Cencora’s multinational distribution footprint and global platform of commercialization services make it a natural partner for manufacturers bringing their products to the market. With the company’s increasing presence in pharma services, it is able to cultivate its relationship with pharma companies during the early development process and position itself as not only a provider of logistics and distribution services but also as an integrated partner for supporting the successful commercialization of its products. These factors are likely to have favored the stock’s growth.
What’s Hurting the COR Stock?
Cencora operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing consolidation of customers and manufacturers, global competitors and regulatory challenges.
The company encounters additional competition from manufacturers, chain drugstores, specialty distributors, and packaging and healthcare technology companies. The increasing competition is likely to affect its business.
COR has been witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for earnings has increased from $13.56 to $13.62 per share.
The consensus mark for fourth-quarter fiscal 2024 revenues is pegged at $77.68 billion, indicating a 12.7% improvement from the year-ago quarter’s reported actuals. The bottom-line estimate is pinned at $3.21, implying year-over-year growth of 12.2%.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , ATI Physical Therapy (ATIP - Free Report) and Aveanna Healthcare (AVAH - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), ATI Physical Therapyand Aveanna Healthcarecarry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth year to date.
ATI Physical Therapy's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.25%.
ATIP's shares have risen 5.5% year to date compared with the industry’s 18.6% growth.
Aveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.5%.
AVAH's shares have surged 104.5% year to date compared with the industry’s15.7% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
Cencora, Inc. (COR - Free Report) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 10.3% year to date compared with the industry’s 7.4% growth. The S&P 500 Index has risen 17.7% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $45.02 billion.
Image Source: Zacks Investment Research
COR’s bottom line is anticipated to improve 11.2% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.59%.
What’s Driving COR’s Growth?
Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the segment in the upcoming quarters.
In the third quarter of fiscal 2024, revenues at U.S. Healthcare Solutions totaled $67.2 billion, up 12.2% year over year. The company continues to witness a strong segmental performance due to growth in all markets and strong demand for specialty products, especially GLP-1 drugs. High demand for the recently approved GLP-1 drugs for diabetes and/or weight loss is likely to continue going forward.
Segmental operating income amounted to $698.3 million, up 9.9% year over year. Higher gross profit (including fees earned from the distribution of government-owned COVID-19 treatments and a gross profit on sales from specialty physician practices) contributed to the upside.
Revenues in the U.S. Healthcare Solutions segment are expected to grow 12-13% in fiscal 2024. Operating income is anticipated to increase 10-12% during the same time frame.
Also, Cencora is expected to benefit from generics growth in the long run, raising investors’ optimism. It is well-positioned to help ensure the smooth entry of its products into the market. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, better economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs and a continued good brand pricing environment should aid. Moreover, the company’s focus on specialty drugs bodes well.
In May, Cencora announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC for approximately $400 million in a private transaction. The company also raised its fiscal 2024 guidance for adjusted earnings per share (EPS), which is now estimated to be in the range of $13.55-$13.65 (previously $13.35-$13.55).
The uptick reflects a lower weighted average diluted share count, partially offset by higher net interest expense due to lower investment balances of cash being used for share repurchases. COR estimates revenues to grow 12% year over year. Total adjusted operating income is expected to improve 10-11% during the same time frame.
Cencora’s multinational distribution footprint and global platform of commercialization services make it a natural partner for manufacturers bringing their products to the market. With the company’s increasing presence in pharma services, it is able to cultivate its relationship with pharma companies during the early development process and position itself as not only a provider of logistics and distribution services but also as an integrated partner for supporting the successful commercialization of its products. These factors are likely to have favored the stock’s growth.
What’s Hurting the COR Stock?
Cencora operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing consolidation of customers and manufacturers, global competitors and regulatory challenges.
The company encounters additional competition from manufacturers, chain drugstores, specialty distributors, and packaging and healthcare technology companies. The increasing competition is likely to affect its business.
Cencora, Inc. Price
Cencora, Inc. price | Cencora, Inc. Quote
Estimate Trend
COR has been witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for earnings has increased from $13.56 to $13.62 per share.
The consensus mark for fourth-quarter fiscal 2024 revenues is pegged at $77.68 billion, indicating a 12.7% improvement from the year-ago quarter’s reported actuals. The bottom-line estimate is pinned at $3.21, implying year-over-year growth of 12.2%.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , ATI Physical Therapy (ATIP - Free Report) and Aveanna Healthcare (AVAH - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), ATI Physical Therapyand Aveanna Healthcarecarry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth year to date.
ATI Physical Therapy's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.25%.
ATIP's shares have risen 5.5% year to date compared with the industry’s 18.6% growth.
Aveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.5%.
AVAH's shares have surged 104.5% year to date compared with the industry’s15.7% growth.